The comparative efficacy of antiseptics against Candida auris biofilms
Since its first report in 2009, the emerging multidrug-resistant pathogenic yeast Candida auris has attracted considerable attention as a source of healthcare associated infections. Alarmingly, it has been attributable for a number of nosocomial outbreaks globally, including a UK intensive care unit, whereby almost 20% of colonised patients developed candidaemia [1]. High transmission within critical care units has been reported, with environmental sampling yielding C. auris from beds and chairs, in addition to multiuse patient equipment [2,3].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Ryan Kean, Emily McKloud, Eleanor M Townsend, Leighann Sherry, Christopher Delaney, Brian L Jones, Craig Williams, Gordon Ramage Source Type: research
More News: Candida | Drugs & Pharmacology | Environmental Health | Intensive Care | Multidrug Resistance | Outbreaks